ROR1 and diffuse large B-cell lymphoma: Antibody drug conjugates (ADC) have not yet been established for use in DLBCL-RS, with ongoing trials of polatuzumab vedotin, a CD79b-directed ADC that has shown efficacy in de novo DLBCL (NCT04679012), and zilovertamab vedotin (ZV), which targets ROR1 on the surface of RS cells (NCT05458297).